Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia.

The prognostic significance of FLT3 mutations in acute promyelocytic leukemia (APL) is not firmly established and is of particular interest given the opportunities for targeted therapies using FLT3 inhibitors. We studied 203 patients with PML-RARA-positive APL; 43% of the patients had an FLT3 mutation (65 internal tandem duplications [ITDs], 19 D835/I836, 4 ITD+D835/I836). Both mutations were associated with higher white blood cell (WBC) count at presentation; 75% of the patients with WBC counts of 10 x 10(9)/L or greater had mutant FLT3. FLT3/ITDs were correlated with M3v subtype (P < .001), bcr3 PML breakpoint (P < .001), and expression of reciprocal RARA-PML transcripts (P = .01). Microarray analysis revealed differences in expression profiles among patients with FLT3/ITD, D835/I836, and wild-type FLT3. Patients with mutant FLT3 had a higher rate of induction death (19% vs 9%; P = .04, but no significant difference in relapse risk (28% vs 23%; P = .5) or overall survival (59% vs 67%; P = .2) at 5 years. In in vitro differentiation assays using primary APL blasts (n = 6), the FLT3 inhibitor CEP-701 had a greater effect on cell survival/proliferation in FLT3/ITD+ cells, but this inhibition was reduced in the presence of ATRA. Furthermore, in the presence of CEP-701, ATRA-induced differentiation was reduced in FLT3/ITD+ cells. These data carry implications for the use of FLT3 inhibitors as frontline therapy for APL.

[1]  H. Dombret,et al.  Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group , 2005, Leukemia.

[2]  M. Segal,et al.  DNA topoisomerase II in therapy-related acute promyelocytic leukemia. , 2005, The New England journal of medicine.

[3]  M. Tallman,et al.  Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Randy Allred,et al.  A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. , 2005, Blood.

[5]  Kyu-Tae Kim,et al.  Internal tandem duplications of the FLT3 gene are present in leukemia stem cells. , 2004, Blood.

[6]  E. Estey,et al.  Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412 , 2004 .

[7]  M. Heinrich,et al.  Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells. , 2004, Blood.

[8]  R. Braziel,et al.  Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis. , 2004, Blood.

[9]  F. Mandelli,et al.  Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. , 2004, Blood.

[10]  R. Arceci,et al.  Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition. , 2004, Blood.

[11]  H. Kantarjian,et al.  Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. , 2004, Blood.

[12]  W. Au,et al.  FLT‐3 aberrations in acute promyelocytic leukaemia: clinicopathological associations and prognostic impact , 2004, British journal of haematology.

[13]  T. Enver,et al.  Acute promyelocytic leukemia: where does it stem from? , 2004, Leukemia.

[14]  M. Levis,et al.  Internal tandem duplication mutation of FLT3 blocks myeloid differentiation through suppression of C/EBPalpha expression. , 2004, Blood.

[15]  Marcos González,et al.  FLT3-activating mutations are associated with poor prognostic features in AML at diagnosis but they are not an independent prognostic factor. , 2004, The hematology journal : the official journal of the European Haematology Association.

[16]  M. Heinrich,et al.  An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  F. Cavalli,et al.  A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. , 2003, Blood.

[18]  D. Liang,et al.  Internal tandem duplication and Asp835 mutations of the FMS‐like tyrosine kinase 3 (FLT3) gene in acute promyelocytic leukemia , 2003, Cancer.

[19]  A. Hagemeijer,et al.  FLT3 and MLL intragenic abnormalities in AML reflect a common category of genotoxic stress. , 2003, Blood.

[20]  M. Tallman,et al.  Long-term follow-up and potential for cure in acute promyelocytic leukaemia. , 2003, Best practice & research. Clinical haematology.

[21]  D. Gilliland.  FLT3-activating mutations in acute promyelocytic leukaemia: a rationale for risk-adapted therapy with FLT3 inhibitors. , 2003, Best practice & research. Clinical haematology.

[22]  J. Radich,et al.  The role of FLT3 in haematopoietic malignancies , 2003, Nature Reviews Cancer.

[23]  M. Levis,et al.  FLT3: ITDoes matter in leukemia , 2003, Leukemia.

[24]  C. Vallejos,et al.  Acute promyelocytic leukaemia in patients originating in Latin America is associated with an increased frequency of the bcr1 subtype of the PML/RARα fusion gene , 2003, British journal of haematology.

[25]  D. Linch,et al.  Flt3 mutations and leukaemia , 2003, British journal of haematology.

[26]  H. Kantarjian,et al.  SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. , 2003, Blood.

[27]  D. Grimwade,et al.  The molecular pathogenesis of acute promyelocytic leukaemia: implications for the clinical management of the disease. , 2003, Blood reviews.

[28]  M. Heinrich,et al.  SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. , 2003, Blood.

[29]  M. L. Le Beau,et al.  A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657. , 2003, Blood.

[30]  P. Bolufer,et al.  Incidence and prognostic value of FLT3 internal tandem duplication and D835 mutations in acute myeloid leukemia. , 2003, Haematologica.

[31]  Axel Benner,et al.  Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. , 2002, Blood.

[32]  D. Small,et al.  Targeted inhibition of FLT3 overcomes the block to myeloid differentiation in 32Dcl3 cells caused by expression of FLT3/ITD mutations. , 2002, Blood.

[33]  F. Mandelli,et al.  Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol , 2002, Leukemia.

[34]  J. Griffin,et al.  The roles of FLT3 in hematopoiesis and leukemia. , 2002, Blood.

[35]  Martin Dugas,et al.  Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. , 2002 .

[36]  G. Ehninger,et al.  Analysis of Flt3-activating Mutations in 979 Patients with Acute Myelogenous Leukemia: Association with Fab Subtypes and Identification of Subgroups with Poor Prognosis , 2022 .

[37]  Doriano Fabbro,et al.  Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. , 2002, Cancer cell.

[38]  Donna Neuberg,et al.  CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). , 2002, Cancer cell.

[39]  B. Smith,et al.  A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. , 2002, Blood.

[40]  K. Deguchi,et al.  Cooperativity between mutations in tyrosine kinases and in hematopoietic transcription factors in AML , 2002, Leukemia.

[41]  J. Allebach,et al.  Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor , 2002, Leukemia.

[42]  U. Jaeger,et al.  Variable prognostic value of FLT3 internal tandem duplications in patients with de novo AML and a normal karyotype, t(15;17), t(8;21) or inv(16). , 2002, The hematology journal : the official journal of the European Haematology Association.

[43]  B. Smith,et al.  A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations. , 2001, Blood.

[44]  R. Tibshirani,et al.  Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[45]  T. Naoe,et al.  Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. , 2001, Blood.

[46]  F. Birg,et al.  A new morphologic classification system for acute promyelocytic leukemia distinguishes cases with underlying PLZF/RARA gene rearrangements. , 2000, Blood.

[47]  T. Ley,et al.  A bcr-3 isoform of RARα-PML potentiates the development of PML-RARα-driven acute promyelocytic leukemia , 1999 .

[48]  D. Grimwade,et al.  CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Presenting White Blood Cell Count and Kinetics of Molecular Remission Predict Prognosis in Acute Promyelocytic Leukemia Treated With All- Trans Retinoic Acid: Result of the Randomized MRC Trial , 2022 .

[49]  T. Ley,et al.  Seed versus soil: the importance of the target cell for transgenic models of human leukemias. , 1999, Blood.

[50]  T. Ley,et al.  A bcr-3 isoform of RARalpha-PML potentiates the development of PML-RARalpha-driven acute promyelocytic leukemia. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[51]  K Wheatley,et al.  The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. , 1998, Blood.

[52]  T. Naoe,et al.  Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia , 1997, Leukemia.

[53]  I. Weissman,et al.  A PMLRARα transgene initiates murine acute promyelocytic leukemia , 1997 .

[54]  I. Weissman,et al.  A PMLRARalpha transgene initiates murine acute promyelocytic leukemia. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[55]  D. Grimwade,et al.  Establishing the presence of the t( 15; 17) in suspected acute promyelocytic leukaemia: cytogenetic, molecular and PML immunofluorescence assessment of patients entered into the M.R.C. ATRA trial , 1996, British journal of haematology.

[56]  T. Lister,et al.  Diagnosis of acute promyelocytic leukaemia by RT‐PCR: detection of PML‐RARA and RARA‐PML fusion transcripts , 1992, British journal of haematology.

[57]  P. Pelicci,et al.  Expression pattern of the RAR alpha-PML fusion gene in acute promyelocytic leukemia. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[58]  R Berger,et al.  NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). , 1991, Blood.

[59]  A. Khwaja,et al.  The effects of rhGM‐CSF on the neutrophil respiratory burst when studied in whole blood , 1990, British journal of haematology.

[60]  C. Bloomfield,et al.  Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  G Flandrin,et al.  Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. , 1985, Annals of internal medicine.

[62]  C. Bloomfield,et al.  Acute promyelocytic leukaemia: a study of 39 cases with identification of a hyperbasophilic microgranular variant , 1982, British journal of haematology.

[63]  Charles Lupton,et al.  The Leeds General Infirmary , 1846, The Hospital.

[64]  T. Wakley.  The Royal Free Hospital , 1854, The Hospital.

[65]  Ogilvie Will,et al.  ABERDEEN ROYAL INFIRMARY.: CASE OF PSOAS ABSCESS ; ANTISEPTIC TREATMENT ; RECOVERY , 1878 .

[66]  Najman,et al.  NB 4 , a Maturation Inducible Cell Line With t ( 15 ; 17 ) Marker Isolated From a Human Acute Promyelocytic Leukemia ( M 3 ) , 2022 .

[67]  Southampton General Hospital , 2022 .